Purdue Pharma L.P.

201 Tresser Blvd
Stamford, CT, 06901-3432  United States
(203) 588-8000
Company Type: Limited Partnership Parent
Need to make updates to your profile? Claim this company to make updates. Claim this company

Purdue Pharma researches, develops, and manufactures prescription and over-the-counter medicines. Products include treatments for chronic and severe pain, including OxyContin, a controlled-release version of oxycodone; HysinglaER, an extended-release hydrocodone drug; and buprenorphine pain patch Butrans. It is also developing opioid addiction therapies and treatments for cancers, ADHD, nervous system disorders, and pain. The company filed for bankruptcy protection in 2019 after facing extensive scrutiny over its opioid-marketing practices. Through the restructuring, the company will convert into a new public-benefit entity.

Try D&B Hoovers Free

Financial Statements

Revenue in USD

Annual Revenue 2018
$709.32 million USD

Dun & Bradstreet collects private company financials for more than 23 million companies in over 200 countries. Find out more.

Company Snapshot

Essential information for a successful call

  •  EMPLOYEES (This Site) 182
  •  EMPLOYEES (All Sites) 2,337
  •  REVENUE (MIL USD) 709.32
  • Incorporated 1991

Get in Touch with 8 Principals*

A D&B Hoovers Subscription is your foot in the door to Purdue Pharma L.P. contact information.
  • Steve Miller
    Partner
  • STEVE MILLER
    Chairman of the Board
  • CRAIG LANDAU
    President and Chief Executive Officer
  • EDWARD B MAHONY
    Chief Financial Officer
See full contact details
Start Your Free Trial

Get full access to D&B Hoovers

With a Hoovers subscription you can get a comprehensive view of Purdue Pharma L.P.

Purdue Pharma L.P.*

8
Principals
See who the company's key decision makers are
26
Corporate Relations
Get the big picture on a company's affiliates and who they do business with.
*Contacts and Principals counts are estimates and may differ from the actual number of contacts available in D&B Hoovers.